The estimated Net Worth of Ajay Madan is at least $9.97 millió dollars as of 28 February 2022. Dr Madan owns over 9,000 units of Crinetics Pharmaceuticals Inc stock worth over $8,980,726 and over the last 4 years he sold CRNX stock worth over $418,038. In addition, he makes $567,527 as Chief Devel. Officer at Crinetics Pharmaceuticals Inc.
Dr has made over 3 trades of the Crinetics Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 9,000 units of CRNX stock worth $178,920 on 28 February 2022.
The largest trade he's ever made was exercising 106,383 units of Crinetics Pharmaceuticals Inc stock on 28 October 2021 worth over $77,660. On average, Dr trades about 32,199 units every 31 days since 2021. As of 28 February 2022 he still owns at least 176,995 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Dr Madan stock trades at the bottom of the page.
Dr. Ajay Madan DABT, Ph.D., D.A.B.T. is the Chief Devel. Officer at Crinetics Pharmaceuticals Inc.
As the Chief Devel. Officer of Crinetics Pharmaceuticals Inc, the total compensation of Dr T at Crinetics Pharmaceuticals Inc is $567,527. There are 4 executives at Crinetics Pharmaceuticals Inc getting paid more, with R. Scott Struthers having the highest compensation of $3,766,660.
Dr T is 53, he's been the Chief Devel. Officer of Crinetics Pharmaceuticals Inc since . There are 13 older and 5 younger executives at Crinetics Pharmaceuticals Inc. The oldest executive at Crinetics Pharmaceuticals Inc is Wendall Wierenga, 72, who is the Independent Chairman of the Board.
Ajay's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG 2, SAN DIEGO, CA, 92121.
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen és Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include: